RAB5A regulates critical cellular pathways, including:
Early Endosome Fusion: RAB5A is required for plasma membrane-early endosome fusion and subsequent vesicle transport .
Rab Conversion: Activated RAB5A recruits effectors (e.g., Rabenosyn-5) to mediate Rab5-to-Rab7 conversion, enabling endosome maturation .
C5aR1 Internalization: In macrophages, RAB5A facilitates internalization of the complement C5a receptor (C5aR1) via early endosomes, modulating inflammatory responses .
Gastric Cancer (GC): Overexpression of RAB5A correlates with advanced GC stages, metastasis, and proliferation. Co-localization with RAB4A enhances endosomal recycling of growth factors like EGF, promoting malignancy .
Breast Cancer: High RAB5A expression predicts sensitivity to trastuzumab emtansine (T-DM1), an antibody-drug conjugate, by enhancing drug internalization .
Exosomal Release: RAB5A regulates exosome secretion (e.g., syndecan, SDCBP) and autophagosome maturation in cancer cells .
RAB5A antibodies are widely used in:
| Stage | RAB5A Expression | RAB4A Expression | Clinical Correlation |
|---|---|---|---|
| Normal Tissue | 20% | 10% | Basal levels |
| Early GC | 60% | 70% | Early-stage malignancy |
| Advanced GC | 90.9% | 100% | Metastasis, poor prognosis |
Mechanism: RAB5A overexpression enhances EGF-induced proliferation via RAB4A co-localization, promoting endosomal recycling of growth factors .
T-DM1 Sensitivity: High RAB5A expression correlates with pathologic complete response (pCR) in HER2+ breast cancer patients treated with T-DM1/pertuzumab .
Biomarker Potential: RAB5A levels stratify patients into responsive (high) and non-responsive (low) groups, validated in I-SPY2 and KAMILLA trials .
Commercial antibodies undergo rigorous validation:
Immunogen Design: Targeting conserved regions (e.g., aa 1–C-terminus) ensures cross-species reactivity .
Purification: Affinity-purified using protein A/G or antigen columns .
Controls: Preimmune IgG or peptide-blocking experiments confirm specificity .